Background: The incidence of isolated testicular relapse (ITR) of acute lymphoblastic leukemia (ALL) has decreased with contemporary treatment strategies, but outcomes are suboptimal with a 58% 5-year overall survival (OS). This study aimed to improve outcome in patients with ITR of B-cell ALL (B-ALL) occurring after 18 months of first clinical remission using intensive systemic chemotherapy and to decrease long-term sequelae by limiting use of testicular radiation.
Results: Overall 5-year event-free survival (EFS)/OS was 65.0 ± 8.8%/73.1 ± 8.3%, with 5-year EFS 62.1 ± 11.0% vs. 72.7 ± 14.4% for patients who did not receive radiation therapy (XRT) (n = 29) compared with those who did (n = 11), respectively (P = 0.64). There were six second bone marrow relapses and six second ITRs. The proportion of second relapses was similar in the patients that received testicular radiation and those who did not. However, the 5-year OS was similar for patients who did not receive XRT (72.6 ± 10.2%) compared with those who did (72.7 ± 14.4%) (P = 0.85).
Conclusions:
A 5-year OS rate of 73.1 ± 8.3% was obtained in children with first ITR of B-ALL occurring after 18 months of CR1 (length of first clinical remission) using intensive chemotherapy and limiting testicular radiation.
INTRODUCTION
Refinement of strategies used to treat children with newly diagnosed acute lymphoblastic leukemia (ALL) has continued to improve survival.
However, relapse in the marrow and extramedullary sites remains problematic and most patients who relapse do not survive. Isolated overt testicular relapse is becoming distinctly less common, with an incidence of approximately 0.5-2% among males in the most recent Children's Cancer Group (CCG) ALL trials in both the standard and high-risk groups. [1] [2] [3] [4] The incidence of testicular relapse has steadily decreased over the past two decades, attesting to the effectiveness of improved systemic therapy in the ability to eradicate disease in the testes and prevent relapse in this sanctuary site. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The major impact of isolated testicular relapse (ITR) is the high incidence of subsequent systemic relapse, though this appears to be directly influenced by length of first clinical remission (CR1). [18] [19] [20] [21] [22] [23] In POG 8304 (1983) (1984) (1985) (1986) (1987) (1988) (1989) , the overall 4-year event-free survival (EFS) among males with occult testicular relapse at completion of therapy was 53 ± 8%, compared to 84 ± 10% for males with late overt ITR (6 months or greater following completion of therapy). 18, 19 A more recent analysis of the CCG database (CCG 1881, CCG 1882, CCG 1901, CCG 1883, CCG 1922, unpublished results) showed a trend to poorer outcome for those with CR1< 18 months versus >18 months (5-year EFS 43% vs. 61%, respectively), though numbers are small and do not reach statistical significance. These findings suggested that a different approach to treatment may be warranted for early and late
ITR.
Endocrine late effects following testicular radiation are significant, with a majority of males requiring hormonal replacement at some stage for induction of puberty or continuing pubertal maturation or both. [24] [25] [26] [27] [28] [29] Radiation also leads to sterility and may result in disturbed sexual function. Age (and pubertal status) at time of radiation as well the radiation dose to the testes are factors in outcome. [30] [31] [32] [33] In light of an anticipated growing number of survivors of ITR and ALL relapse in general, consideration of significant late effects potentially impacting quality of life should be considered seriously in the decision regarding treatment. 34, 35 In this trial, we sought to determine whether testicular radiation may be able to safely be omitted while maintaining or improving EFS. The approach taken in this study was to use intensive systemic chemotherapy to improve overall EFS and to allow elimination of testicular radiation by using higher doses of methotrexate (MTX, shown in preclinical studies to penetrate the blood-testis barrier) and other drugs effective in the treatment of ITR. The Children's Oncology Group (COG) protocol AALL02P2 was designed with the primary objective to eliminate testicular radiation by further intensifying chemotherapy with proven agents that enter into the testicular interstitium in adequate cytocidal concentrations (particularly high-dose
MTX [HDMTX]
). Secondary objectives included the documentation of marrow minimal residual disease (MRD) at time of relapse and assessment of pretreatment MRD as it correlates with outcomes.
PATIENTS AND METHODS

Patients
COG protocol AALL02P2 opened to patient entry November 1, 2004 and closed to accrual January 7, 2011. This protocol was designed to treat patients with ALL and late isolated extramedullary relapse, defined as a CR1 ≥18 months. Eligibility for participation on study included age 18 months to <30 years at time of relapse, history of ALL in first bone marrow (BM) remission with isolated central nervous system (CNS) and/or testicular relapse, and length of CR1 ≥18 months from time of initial diagnosis. BM evaluation was required to be M1 by morphology (less than 5% blasts). Patients with Down syndrome were not eligible due to increased sensitivity to MTX. Testicular relapse was suspected on the basis of unilateral or bilateral testiculomegaly. Testicular biopsy was required for confirmation of relapse.
Treatment
All patients enrolled on the study received a common induction, consolidation, intensification I, reinduction, and intensification II, with concomitant prophylactic intrathecal triple chemotherapy (MTX, cytarabine, hydrocortisone) dosed by age. Maintenance therapy was stratified according to site of extramedullary relapse ( BM samples taken prior to initiation of treatment were assessed for MRD using flow cytometry and PCR analysis for clonality (both were optional). 36 These samples were requested to be collected at the time of determination of possible marrow involvement and to be available for comparison later in the event of systemic relapse. The level of MRD also was to be correlated with EFS to ascertain its predictive value.
Study design and statistical methods
Primary endpoints were EFS and overall survival (OS) from the time of enrollment, as compared to historical outcomes. EFS was calculated as the time from enrollment to first event (induction death, induction failure, relapse at any site, second malignant neoplasm, or remission death from any cause) or last contact, and OS was defined as the time from enrollment to death from any cause or last contact. Fiveyear EFS and OS are presented in this report. OS rates were estimated using the Kaplan-Meier method and the corresponding standard deviations were obtained with Peto's method. 37, 38 The two-sided log-rank test was used for comparison of survival curves between groups. P-values < 0.05 were considered statistically significant. Data were frozen in September, 2016.
RESULTS
Patients characteristics
A total of 40 patients were enrolled, with a median age at the time of initial diagnosis and enrollment on AALL02P2 of 4.6 years and 8.9
years, respectively. Most patients (75%) had been classified as standard risk (age >1 and <10 years and initial WBC < 50,000/ l) using the NCI criteria at the time of their initial diagnosis of ALL (26 standard risk, nine high risk, one infant, and four unknown). High-risk patients are those with age ≥ 10 years or WBC ≥ 50,000/ l at diagnosis. 39 Most patients had received front-line therapy according to standard CCG or POG ALL protocols. The demographics are presented in Table 2 . Of 166 eligible patients with either isolated CNS or testicular relapse enrolled on AALL02P2, 42 of these patients with isolated late testicular relapse were enrolled on this protocol stratum. Of these, 40 patients had B-ALL and two T-ALL: this analysis is limited to those patients with B-ALL. All patients had biopsy-proven testicular relapse.
TA B L E 2 Patient characteristics AALL02P2
Response to therapy
As per protocol design, only patients who did not have a complete response to induction chemotherapy received testicular radiation. Fourteen events occurred including 12 relapses, one death in remission, and one second malignant neoplasm (Table 3) . Of the 12 patients experiencing a subsequent relapse, six had a second ITR and six had a systemic (BM) relapse. One of these patients experienced early BM relapse and was removed from protocol therapy after induction (this patient was considered unevaluable per protocol guidelines and not included in analysis of EFS and OS based). This patient had a testicular response and did not receive radiation. Among those patients who suffered a subsequent systemic relapse, two occurred in the group that did not receive testicular radiation (for a total of three patients) and three in patients that received testicular radiation due to persistence of biopsy-proven testicular leukemia at the end of induction therapy.
None of the 11 patients that received testicular irradiation had a second testicular relapse. Among the 29 patients who did not receive testicular irradiation, 23 (80%) did not have a second testicular relapse, while six (20%) had a testicular relapse. Fourteen patients had clinical resolution of testicular leukemia at the end of induction, and three of these had a second testicular relapse. Thirteen patients had persistent testicular enlargement at end of induction but a negative biopsy, and three of these had a second testicular relapse.
A secondary objective of this study was to determine the presence of BM involvement detectable as MRD at the time of isolated extramedullary relapse. MRD was measured in the BM at the time of diagnosis of ITR using previously described flow cytometry techniques. 36 
EFS
Five-year EFS for B-ALL patients with ITR was 65.0 ± 8.8%, whereas 5-year OS was 73.1 ± 8.3% (Figure 2A and 2B 
Toxicity
Toxicities in this cohort where those expected following 12 months of intensified systemic chemotherapy. From a total of 29 patients who entered and received maintenance chemotherapy, 26 of them were delayed by 8 weeks or more (≥14 months from study entry). Therefore, although only one toxic death (infection) was seen in this cohort, the intensity of this regimen led to multiple delays in therapy.
The most common toxicity experienced by patients on this trial was myelosuppression, with 31 and 15 episodes of grade 3/4 neutropenia and thrombocytopenia, respectively (Table 4) . Myelotoxicity was more severe following the phases of therapy that included high-dose cytarabine. There were 26 episodes of febrile neutropenia, 64% of which occurred during consolidation and intensification II.
Although the incidence of febrile neutropenia was considerable, only one episode of sepsis occurred, nevertheless most patients (26/29) who entered and received maintenance chemotherapy experienced significant delays highlighting the intensity of the regimen. There were a total of seven episodes (17%) of severe hypersensitivy reactions (anaphylaxis) to PEG-asparaginase. Other observed toxicities included F I G U R E 2 Event-free survival (EFS) and overall survival (OS) of ITR patients with B-ALL enrolled on the Children's Oncology Group (COG) AALL02P2 and stratified by testicular radiation. Five-year EFS for B-ALL patients with ITR was 65.0 ± 8.8% (Figure 2A ), whereas 5-year OS was 73.1 ± 8.3% ( Figure 2B ). Five-year EFS was 72.7 ± 14.4% for those who receive testicular radiation and 60.7 ± 11.5% for patients who did not (Figure 2C) . In comparison, 5-year OS for patients with ITR treated with testicular radiation was 72.7 ± 14.4% compared to 71.4 ± 10.6% for patients who did not receive testicular radiation ( Figure 2D) 
TA B L E 4 AALL02P2 grade 3 and 4 toxicities
DISCUSSION
In this report, we describe 40 children with first late (CR1 ≥ 18 for the entire cohort. More importantly, although we saw a nonstatistically significant trend to improved 5-year EFS for those who received testicular radiation compared to patients who did not (72.7 ± 14.4% vs.
62.1 ± 11.0%, P = 0.64), 5-year OS for patients with ITR treated with or without testicular radiation was identical (72.7 ± 14.4% compared to 72.6 ± 10.2%, respectively).
Therefore, using a regimen that included 12 months of intensive systemic chemotherapy using drugs known to penetrate the bloodtestis barrier followed by maintenance therapy, we were able to avoid testicular radiation in two-thirds of patients. This led to the avoidance of potential long-term toxicity associated with testicular radiation in patients who exhibited clearance of testicular leukemia at the end of induction therapy, without decreasing OS.
Prior to embarking on this clinical trial we were intrigued with a report from The Dutch Late Effects study group on outcomes in five males with late ITR in which testicular radiation (previously a mainstay of treatment for ITR in addition to systemic retreatment) was omitted. 40 Our study sought to answer the question if testicular radi- were available for MRD analysis using flow cytometry. We found evidence of systemic involvement at the time of ITR in only three patients.
These findings contrast with previous reports using PCR-based detection methods for MRD determination in which most patients were found to have MRD positivity in the BM at the time of extramedullary relapse. 43, 44 It is unclear at this time what the basis for this discrepancy is, although it is possible that it reflects the higher level of sensitivity of PCR-based methods, differences in the populations of patients studied or differences in therapy when comparing cohorts across different treatment eras, or a combination of these factors.
This intensive multiagent regimen was well tolerated in this cohort.
As expected, myelosuppression leading to episodes of febrile neutropenia were the most common toxicities. The high incidence of myelosuppression led to ≥8 weeks delays in entering maintenance chemotherapy for many patients on this study. Based on EFS comparisons with historical controls, these delays did not impact negatively on EFS or OS for ITR patients treated on this study. Only one toxic death was observed in this group of ITR patients due to cytomegalovirus pneumonitis complicated with multiorgan failure. In addition, seven (17%) patients experienced severe hypersensitivity reactions (anaphylaxis) in this regimen that uses intensive dosing of PEG-asparaginase.
Other toxicities reported in this cohort were similar to what is usually observed for similar intensive multiagent ALL regimens. 
